News

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared to chemoradiotherapy alone in patients with high-risk locally advanced cervical cancer.

The novel ROS1 inhibitor zidesamtinib demonstrated promising early activity in heavily pretreated patients with advanced ROS1-fusion-positive non–small cell lung cancer, including in those treated with other next-generation TKIs.

A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not significantly affect overall survival compared to the standard dose.

The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated non–small cell lung cancer when compared to dostarlimab alone.

Findings from the DESTINY-Gastric03 study support the further exploration of the antibody-drug conjugate trastuzumab deruxtecan for the first-line treatment of patients with advanced HER2+ gastric, esophageal, and GEJ cancers.

The study found that lenvatinib continued to demonstrate improved efficacy in patients with radioiodine-refractory differentiated thyroid cancer.

When added to tivozanib, nivolumab did not lead to improved clinical outcomes in metastatic renal cell carcinoma.

A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan treatment in patients with previously treated patients with advanced clear cell renal cell carcinoma.

The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to nivolumab and chemotherapy alone.

Shirish M. Gadgeel, MD, discusses research that he is particularly excited to see presented at the 2024 European Society for Medical Oncology Congress.

The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of prior prophylactic cranial irradiation or concurrent chemoradiotherapy use.

Data from the phase 2 PECATI trial support the use of lenvatinib plus pembrolizumab as a potential standard treatment for patients with advanced B3-thymoma and thymic carcinoma.

The BR.31 trial found that adjuvant durvalumab did not improve disease-free survival in patients with non-small cell lung cancer, regardless of PD-L1 expression.

Sergio A. Giralt, MD, discusses how to determine which patient is a candidate for transplant and the optimal time to perform a transplant in patients with myelodysplastic syndrome.

Experts review the case of a 68-year-old woman diagnosed with primary myelofibrosis.

The subcutaneous version of the cancer treatment atezolizumab is approved in all adult intravenous indications, including in lung, liver, and skin cancers.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.

The investigational new drug application for VNX-101, a gene therapy aimed at treating CD19-positive acute lymphoblastic leukemia, has been approved by the FDA.

The phase 3 Shorespan-007 trial will compare bomedemstat with hydroxyurea in patients with treatment-naive essential thrombocythemia.

Alessandra Ferrajoli, MD, discusses the session she was a part of at the 2024 Society of Hematologic Oncology Annual Meeting.

Findings from a real-world study showed that zanubrutinib was associated with lower rates of treatment switching and patients receiving subsequent therapy compared with acalabrutinib and ibrutinib in patients with CLL or SLL.

The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.

The digital twin trial arm demonstrated a 52.7% overall response rate at 6 months for prednisone in chronic GVHD, aligning with real-world data.

Tebapivat, a novel pyruvate kinase activator, is being investigated for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

HER2DX has shown a strong association between ERBB2 mRNA and survival in patients with HER2-positive breast cancer.

The investigational agent certepetide has been granted FDA orphan drug designation for the treatment of patients with cholangiocarcinoma.

The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.

In this preview, we highlight the key late-breaking abstracts to be presented at the 2024 ESMO Congress across various tumor types that may impact clinical practice.